Onyx Scientific is investing in a new facility at its UK site in order to prepare for the approval of a commercial API license.   The new facility, which represents a £3 million ($4 million) investment, is currently in the design phase and the building work will begin at the start of 2021, in preparation for the license approval. It will enable the CDMO to meet demand for flexible, small-scale drug substance manufacture, supporting customers from the moment a lead molecule is identified, into Ph...